Otros idiomas Syntara Limited

Acciones

SNT

AU0000312480

Precio de cierre Australian S.E. Otros sitios de cotización 00:00:00 10/05/2024			Varia. Cinco días.	Varia. 1 de enero.
0,018 ^AUD	+12,50 %		+20,00 %	-10,00 %

30/04	Transcript : Syntara Limited, Q3 2024 Earnings Call, Apr 30, 2024
29/02	Syntara Limited informa de los resultados de ganancias para el semestre finalizado el 31 de diciembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Syntara Reaches 50% Recruitment in Phase 2 Trial for Bone Marrow Cancer Treatment	10/04
Syntara Limited Reports Earnings Results for the Half Year Ended December 31, 2023	29/02
Syntara to Begin Phase Two Study for SNT-5505 Combination Therapy Later in 2024 After Government Grant	14/02
Syntara Opens Up to AU$2 Million Share Purchase Plan	29/12
Syntara Starts Dosing Patients in Phase Two Trial of Drug Candidate	13/12
Syntara Receives AU$5.2 Million R&D Tax Rebate	05/12
Pharmaxis Doses First Patient in Phase Two Sleep Trial	10/11
University of Birmingham : Promising target for liver disease treatments identified; Inhibiting a protein involved in liver inflammation has the potential to reduce or stop fibrosis in patients with non-alcoholic steatohepatitis, trial finds	08/11
Pharmaxis Ltd Reports Earnings Results for the First Quarter Ended September 30, 2023	31/10/23
Pharmaxis Sells Mannitol Business; Shares Fall 3%	19/10/23
Arna Pharma Pty Ltd completed the acquisition of Mannitol respiratory business of Pharmaxis.	19/10/23
BTC Health Arm to Continue Distributing Bronchitol, Aridol in Australia	04/10/23
Pharmaxis to focus on clinical-stage drug development	03/10/23
Pharmaxis to Change Name Amid Restructure, Appoints Chair	03/10/23
Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis.	03/10/23
Australian Bourse Halts Trading in Pharmaxis’ Securities	02/10/23
Pharmaxis Ltd Reports Earnings Results for the Full Year Ended June 30, 2023	28/08/23
Pharmaxis Secures $4 Million R&D Loan	08/08/23
Pharmaxis says majority of patients in fibrosis trial see significant improvement	13/07/23
Pharmaxis Logs Positive Results in Cancer Trial	13/07/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Syntara Limited

Acciones

SNT

AU0000312480

Otros idiomas

Filtros